Combination of pegylated interferon [peginterferon-alfa] and ribavirin as therapy for patients with chronic hepatitis C with and without renal disease.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ribavirin (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- 08 Nov 2013 Biomarkers information updated
- 07 Jul 2010 Actual end date (June 2010) added as reported by ClinicalTrials.gov.
- 07 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.